EQL Pharma AB's Annual General Meeting Approves Financial Statements, No Dividend Declared
EQL Pharma AB held its Annual General Meeting on August 20, 2026. The meeting approved the company's and its group's financial statements and resolved not to distribute any dividend for the 2025/2026 financial year.
EQL Pharma AB's Annual General Meeting, held on August 20, 2026, has approved the company's and its consolidated financial statements. A decision was also made regarding the allocation of the company's results.
The meeting resolved to adopt the income statement and balance sheet, as well as the consolidated versions. Following the board of directors' proposal outlined in the annual report, no dividend will be paid for the financial year 2025/2026.
The annual general meeting is a statutory gathering where key financial decisions are made. This year's meeting focused on the adoption of financial reports and the subsequent distribution of profits.
By retaining the year's earnings, EQL Pharma aims to strengthen its financial position and support future strategic initiatives, aligning with common practices for companies prioritizing growth and reinvestment.